Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma.
Sanjay Sharma,Michael H Neale,Federica Di Nicolantonio,Louise A. Knight,Pauline A. Whitehouse,Stuart Mercer,Bernard Higgins,Alan Lamont,Richard H. Osborne,Andrew C Hindley,Christian M. Kurbacher,Ian A. Cree +11 more
Reads0
Chats0
TLDR
The results show similar response rates to previous studies using ATP-TCA directed therapy in recurrent ovarian cancer, and the assay shows high evaluability and adds weight to the reproducibility of results from different centres.Abstract:
Background
We wished to evaluate the clinical response following ATP-Tumor Chemosensitivity Assay (ATP-TCA) directed salvage chemotherapy in a series of UK patients with advanced ovarian cancer. The results are compared with that of a similar assay used in a different country in terms of evaluability and clinical endpoints.read more
Citations
More filters
Journal ArticleDOI
Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery.
TL;DR: The TCA with established human tumour xenografts has an important role in current drug discovery strategies and a number of novel agents were active; these are now in advanced preclinical development or clinical trials.
Journal ArticleDOI
Pharmaceutical Management of Ovarian Cancer: Current Status.
TL;DR: The anti-angiogenic agent bevacizumab has been shown to be clinically active when added to chemotherapy and delivered as a “maintenance” strategy in the front-line, platinum-sensitive recurrent and platinum-resistant settings.
Journal ArticleDOI
A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer
TL;DR: This small randomized clinical trial has documented a trend towards improved response and progression-free survival for assay-directed treatment for patients with platinum-resistant recurrent ovarian cancer, although a larger trial is required to confirm this.
Journal ArticleDOI
Pharmaceutical Management of Ovarian Cancer
TL;DR: Reasonable goals of therapy in women with recurrent or resistant ovarian cancer are to improve overall survival, reduce the severity (and delay the occurrence of symptoms) of symptoms and optimize overall quality of life.
Journal ArticleDOI
Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay.
Holly H. Gallion,W.A. Christopherson,Robert L. Coleman,Leslie R. DeMars,Thomas J. Herzog,S. Hosford,H. Schellhas,Alan Wells,B.-U. Sevin +8 more
TL;DR: Data indicate that the ChemoFx® assay is predictive of PFI in ovarian cancer, and the incorporation of assay information into treatment selection has the potential to improve clinical outcomes in Ovarian cancer patients.
References
More filters
Journal ArticleDOI
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse,Susan G. Arbuck,Elizabeth Eisenhauer,Jantien Wanders,Richard Kaplan,Larry Rubinstein,Jaap Verweij,Martine Van Glabbeke,Allan T. van Oosterom,Michaele C. Christian,S. Gwyther +10 more
TL;DR: A model by which a combined assessment of all existing lesions, characterized by target lesions and nontarget lesions, is used to extrapolate an overall response to treatment is proposed, which is largely validated by the Response Evaluation Criteria in Solid Tumors Group and integrated into the present guidelines.
Journal ArticleDOI
Cancer statistics, 2001.
TL;DR: Estimates of the number of new cancer cases and deaths expected in the US in the current year and the most recent data on cancer incidence, mortality, and survival reveal large disparities in cancer incidence and mortality across racial/ethnic groups.
Journal ArticleDOI
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
William P. McGuire,William J. Hoskins,William J. Hoskins,Mark F. Brady,Paul R. Kucera,Edward E. Partridge,Katherine Y. Look,Daniel L. Clarke-Pearson,Martin Davidson +8 more
TL;DR: In this paper, the authors compared two combinations, cisplatin and cyclophosphamide and paclitaxel, in women with ovarian cancer, and found that the alkylating agent and a platinum coordination complex have high response rates in advanced ovarian cancer.
Journal ArticleDOI
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
TL;DR: The comparable efficacy, favorable safety profile, and convenient dosing support the role of PLD as a valuable treatment option in patients with epithelial ovarian carcinoma that recurred after or didn't respond to first-line, platinum-based chemotherapy.